Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapies for non-small cell lung cancer (NSCLC) have significantly improved patient outcomes.
• Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are key targets in NSCLC treatment.
• EGFR and ALK alterations are typically considered mutually exclusive, influencing treatment response.

Purpose of the Study:

• To present a case of synchronous NSCLC with discordant EGFR and ALK mutation profiles.
• To discuss the clinical implications of coexisting oncogenic drivers in lung cancer.
• To emphasize the importance of comprehensive molecular profiling in NSCLC patient follow-up.

Main Methods:

• Case report detailing the progression of a patient with synchronous lung cancers.
• Analysis of tumor mutation profiles, specifically focusing on EGFR and ALK.
• Review of therapeutic strategies in the context of coexisting driver mutations.

Main Results:

• The patient presented with synchronous lung cancers exhibiting a discordant mutation profile (e.g., one tumor with EGFR mutation, another with ALK rearrangement).
• This discordant profile has significant implications for selecting appropriate targeted therapies.
• The case illustrates the complexity of molecular heterogeneity in NSCLC.

Conclusions:

• Synchronous lung cancers can harbor distinct oncogenic drivers, challenging traditional treatment paradigms.
• Comprehensive molecular profiling is crucial for accurate diagnosis and personalized treatment of NSCLC patients with multiple tumors.
• Understanding coexisting driver mutations is essential for optimizing therapeutic strategies and improving patient survival.